We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

BRUKER

BRUKER offers high-performance scientific instruments and high-value analytical and diagnostic solutions that enable ... read more Featured Products: More products

Download Mobile App




Gastrointestinal PCR Assay Offers Rapid, Culture-Free Pathogen Identification

By LabMedica International staff writers
Posted on 17 Apr 2023
Print article
Image: The LiquidArray Gastrointestinal assay detects up to 26 pathogens from stool samples in a two-well format (Photo courtesy of Bruker)
Image: The LiquidArray Gastrointestinal assay detects up to 26 pathogens from stool samples in a two-well format (Photo courtesy of Bruker)

Gastroenteritis involves inflammation of the stomach and intestines' lining, typically characterized by diarrhea and/or vomiting. Gastrointestinal pathogens can cause life-threatening diseases, especially among children, immunosuppressed individuals, and the elderly. While most cases resolve within days, severe or persistent cases may necessitate hospitalization. Testing stool samples for potential causative agents—bacteria, viruses, parasites, and toxins—creates a substantial diagnostic burden in healthcare facilities. Now, a new syndromic panel for gastrointestinal infections that identifies 26 gastroenteritis-causing pathogens, including bacteria, viruses, parasites, and related toxins, aims to streamline routine procedures and enhance diagnostic efficiency.

Bruker Corporation’s (Billerica, MA, USA) new LiquidArray Gastrointestinal is a syndromic panel for gastrointestinal infections. The assay employs LiquidArray, a next-generation multiplexing technology, to detect up to 26 pathogens from stool samples using a two-well format that supports routine laboratory throughput needs. Introduced on the high-precision FluoroCycler XT thermocycler, LiquidArray merges innovative probe and thermocycling technologies with results-at-a-glance visualization for simultaneous analysis of multiple targets from a single sample. The integrated FluoroSoftware XT-IVD generates easy-to-understand results, expediting clinical decisions.

LiquidArray Gastrointestinal is validated on the GenoXtract fleXT, a dependable, automated system for extracting nucleic acid from patient samples and setting up PCR plates. Barcode-supported robotic sorting minimizes manual intervention. Validated processing of LiquidArray Gastrointestinal on the GenoXtract fleXT offers a convenient walk-away solution tailored for dynamic laboratory environments. This equips high-throughput clinical labs with a fully integrated workflow from sample to result. The test is validated for use with stool samples, and a stool buffer developed for LiquidArray Gastrointestinal enables stabilization and storage of samples to be tested. The kit includes reagents for up to 48 reactions.

“The new LiquidArray Gastrointestinal is a next-generation syndromic panel with amazing pathogen coverage. It is ideal for laboratories which are interested in a broad screening approach to detect most pathogens in one run,” said Dr. Wolfgang Pusch, President of the Bruker Microbiology & Infection Diagnostics division.

Related Links:
Bruker Corporation 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.